SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

27 Jul 2016 Evaluate

Lupin has informed about a Press Release dated July 27, 2016 titled ‘Lupin Receives Tentative Approval for Generic Lexiva Tablets, 700 mg from US FDA’.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2265.15 -112.75 (-4.74%)
11-May-2026 13:08 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.20
Dr. Reddys Lab 1293.20
Cipla 1314.50
Zydus Lifesciences 944.10
Lupin 2265.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×